Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Gagua Clinic | Healthcare Services | 22.4% | 81st pct | 268 |
| Academician Vakhtang Bo… | Healthcare Services | 17.7% | 73rd pct | 268 |
| Jerarsi | Healthcare Services | — | no FY data | 268 |
| Israeli-Georgian Medica… | Healthcare Services | — | no FY data | 268 |
| Chachava Clinic | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 2 of 5 peers filed FY2024. Switch to FY2023 (5 of 5).
| Ratio — FY 2024 | Gagua Clinic | Academician Vakhtang Bo… | Jerarsi | Israeli-Georgian Medica… | Chachava Clinic |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 87.0% | 79.9% | — | — | — |
| EBITDA Margin | 22.4% | 17.7% | — | — | — |
| EBITDAR | 6,534 | 4,938 | — | — | — |
| EBITDAR Margin | 22.4% | 17.7% | — | — | — |
| EBIT Margin | 19.9% | 9.4% | — | — | — |
| Net Profit Margin | 18.8% | 8.7% | — | — | — |
| Operating Expense % of Sales | 67.7% | 62.8% | — | — | — |
| Returns | |||||
| Return on Assets (ROA) | 24.9% | 10.8% | — | — | — |
| Return on Equity (ROE) | 29.9% | 14.1% | — | — | — |
| ROIC [EBIT / Invested Capital] | 30.8% | 14.6% | — | — | — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 7.5% | 13.2% | — | — | — |
| Debt-to-Equity | 0.09x | 0.17x | — | — | — |
| Debt-to-EBITDA | 0.25x | 0.60x | — | — | — |
| Equity-to-Assets | 83.4% | 76.2% | — | — | — |
| Net Debt | 520 | 846 | — | — | — |
| Cash & Equivalents | 1,136 | 2,134 | — | — | — |
| Total Debt | 1,656 | 2,981 | — | — | — |
| Liquidity & working capital | |||||
| Current Ratio | 1.06x | 3.28x | — | — | — |
| Quick Ratio | 1.02x | 2.93x | — | — | — |
| Cash Ratio | 0.35x | 0.78x | — | — | — |
| Total Current Assets | 3,477 | 8,973 | — | — | — |
| Total Current Liabilities | 3,289 | 2,735 | — | — | — |
| Inventory | 136 | 957 | — | — | — |
| Trade Receivables | 2,205 | 5,882 | — | — | — |
| Trade Payables | 2,005 | 2,389 | — | — | — |
| Net Working Capital | 188 | 6,238 | — | — | — |
| Net Working Capital % of Revenue | 0.6% | 22.3% | — | — | — |
| Trade Working Capital | 336 | 4,449 | — | — | — |
| Trade Working Capital % of Revenue | 1.2% | 15.9% | — | — | — |
| Change in Trade Working Capital | N/A | N/A | — | — | — |
| Turnover & efficiency | |||||
| Inventory Turnover | 27.88x | 5.87x | — | — | — |
| Days Inventory Outstanding (DIO) | 13.1 | 62.2 | — | — | — |
| Receivables Turnover | 13.24x | 4.75x | — | — | — |
| Days Sales Outstanding (DSO) | 27.6 | 76.9 | — | — | — |
| Payables Turnover | 1.89x | 2.35x | — | — | — |
| Days Payable Outstanding (DPO) | 193.0 | 155.3 | — | — | — |
| Cash Conversion Cycle | -152.4 days | -16.2 days | — | — | — |
| Asset Turnover | 1.33x | 1.24x | — | — | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 6,334 | 4,396 | — | — | — |
| Free Cash Flow (OCF − Capex proxy) | 4,680 | 2,092 | — | — | — |
| Cash Conversion (OCF / EBITDA) | 96.9% | 89.0% | — | — | — |
| Dividends Declared | 3,810 | 0 | — | — | — |
| Dividend Payout Ratio | 69.4% | 0.0% | — | — | — |